Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Notice to Our Valued Users

Elsevier has made the difficult decision to close PracticeUpdate permanently. There will be no new content published, effective immediately. Although we are all disappointed by this news, we are incredibly grateful for your engagement and support over the years.

We thank the Editorial Boards, Advisory Boards, and Editorial Contributors for their many years of dedication to educating the healthcare community. Our appreciation extends to the many contributors who have shared their valuable time and expertise to help us parse the latest research over the years.

We encourage you to explore our other offerings such as ScienceDirect and ClinicalKey, which continue to provide valuable insights and information to help you excel in your practice.

If you have any questions or need assistance, please see the FAQs section or contact the support team. Thank you for being a part of the PracticeUpdate community!

featured

Published in Metastatic Breast Cancer

Journal Scan / Research · January 27, 2022

64Cu-DOTA-Trastuzumab and Response to Trastuzumab Emtansine

Journal of Nuclear Medicine

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Article Citation

Journal of Nuclear Medicine

Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study

J. Nucl. Med. 2021 Dec 02;[EPub Ahead of Print], JE Mortimer, JR Bading, PH Frankel, M Caroll, Y Yuan, J Park, L Tumyan, N Gidwaney, EK Poku, JE Shively, D Colcher

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Notice to Our Valued Users

Metastatic Breast Cancer

64Cu-DOTA-Trastuzumab and Response to Trastuzumab Emtansine

Additional Info

Use of 64Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study

Further Reading

Final Note From the Metastatic Breast Cancer Editors

Acceptance and Commitment Therapy for Fatigue Interference With Functioning in Patients With Metastatic Breast Cancer

CYP2D6 Activity in Patients With Metastatic Breast Cancer Treated With Single-Agent Tamoxifen

Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease

Effect of RET Overexpression on Brain Metastatic Competency in Luminal Breast Cancer

Immune Checkpoint Inhibitors for Patients With Metastatic Inflammatory TNBC

Attrition Between Lines of Therapy and Real-World Outcomes in Patients With HER2-Positive Metastatic Breast Cancer

Impact of Molecular Tumor Board Recommendations on Clinical Outcomes in Patients With Metastatic Breast Cancer

PD-1/PD-L1 Immune Checkpoint Inhibitors for Unresectable Locally Advanced or Metastatic TNBC

Efficacy of Everolimus Combined With Hormonal Treatment Following CDK4/6 Inhibitor Therapy

2024 Top Story in Metastatic Breast Cancer: First-Line Inavolisib, Palbociclib, and Fulvestrant in Patients With PIK3CA-Mutated, HR-Positive Metastatic Breast Cancer

Recently Updated